High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
Status:
Not yet recruiting
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation
therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing
androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop
normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks
of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This
trial may help researcher determine if high-dose vitamin D helps keep bones strong, lowers
number of falls, and lessens fatigue in men getting androgen-deprivation therapy.
Phase:
Phase 3
Details
Lead Sponsor:
University of Rochester NCORP Research Base
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins